Navigation Links
SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, that SGI-1252, its JAK2 kinase inhibitor, prevents tumor cell proliferation in vivo (abstract #741).

In an oral presentation titled "SGI-1252: A Potent Small Molecule JAK2 Inhibitor," Dr. Steven Warner, Manager of Discovery Biology, highlighted how SuperGen scientists used the company's CLIMB(TM) technology to identify SGI-1252 as a possible JAK2 inhibitor. Dr. Warner presented data indicating that SGI-1252 selectively inhibits wildtype and mutant JAK2 activity in cancer cell lines, resulting in inhibition of STAT5 phosphorylation as well as a reduction in Bcl-XL expression. SGI-1252 was also shown to prevent tumor growth in mouse xenograft models. Pharmacokinetic studies indicate that SGI-1252 is orally bioavailable.

"SGI-1252 has shown potent and selective inhibition of JAK2 cellular signaling pathways that are involved in cancer cell proliferation. Moreover, as SGI-1252 does not target JAK3, we expect no negative clinical impact on patients' immune systems," said Dr. James Manuso, SuperGen's President and CEO. "We are optimistic that SGI-1252 may be effective in treating leukemia, lymphoma and myeloproliferative disorders and look forward to advancing this promising candidate into the clinic."

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.


Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Business Manager, Investor Relations


Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: E-mail:

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGens PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
4. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
5. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
8. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
11. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Post Your Comments:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):